TP53 and cancer: It should be that it has a synergistic effect with TP53, both have oncogenic properties, so when TP53 mutation cells enhance other oncogenic signaling pathways, the expression of hsa-mir-145-5p is increased, and high expression of hsa-mir-145-5p significantly enhances the survival rate of patients (high expression is 64 samples, low to medium expression is 192 samples), it was further demonstrated that hsa-mir-145-5p has cancer inhibitory effect.